Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).
Authors
Austin G. Duffy
National Cancer Institute at the National Institutes of Health, Bethesda, MD
Austin G. Duffy, Drew Pratt, David E Kleiner, Donna Mabry, Suzanne Fioravanti, Melissa Walker, William Douglas Figg, Seth M. Steinberg, Victoria Anderson, Elliot Levy, Venkatesh Krishnasamy, Bradford J. Wood, Tim F. Greten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Clinical Trials
Clinical Trial Registration Number
NCT01853618
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 88)
DOI
10.1200/JCO.2017.35.7_suppl.88
Abstract #
88
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).
First Author: Austin G. Duffy
Poster
2016 ASCO Annual Meeting
Tremelimumab: A monoclonal antibody against CTLA-4—in combination with subtotal ablation (trans catheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).
First Author: Austin G. Duffy
Poster
2016 Gastrointestinal Cancers Symposium
![Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).](https://d201v5jt9ylckg.cloudfront.net/173/11384/120467/120467_poster_pv.jpg)
Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).
First Author: Austin G. Duffy
Poster
2015 ASCO Annual Meeting
A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).
First Author: Austin G. Duffy